4//SEC Filing
Eansor Norman David 4
Accession 0001209191-23-035617
CIK 0001094038other
Filed
Jun 7, 8:00 PM ET
Accepted
Jun 8, 9:35 PM ET
Size
12.9 KB
Accession
0001209191-23-035617
Insider Transaction Report
Form 4
EANSOR N DAVID
Director
Transactions
- Purchase
Common Stock
2021-03-16$17.50/sh+14,285$249,988→ 16,713 total - Gift
Common Stock
2021-03-25−14,285→ 2,428 total - Gift
Common Stock
2021-03-25+7,142→ 7,142 total(indirect: By Trust) - Gift
Common Stock
2021-03-25+7,142→ 7,142 total(indirect: By Trust) - Award
Stock Option (right to buy)
2023-06-06+8,000→ 8,000 totalExercise: $1.72Exp: 2033-06-05→ Common Stock (8,000 underlying)
Footnotes (3)
- [F1]Reflects a 10-1 reverse stock split which became effective on January 16, 2023.
- [F2]The Reporting Person transferred these shares to a trust of which the Reporting Person is the trustee. The Reporting Person's immediate family is the sole beneficiary of the trust.
- [F3]This option vests on June 6, 2024, subject to the Reporting Person's continued service as a director through the vesting date.
Documents
Issuer
Marker Therapeutics, Inc.
CIK 0001094038
Entity typeother
Related Parties
1- filerCIK 0001270905
Filing Metadata
- Form type
- 4
- Filed
- Jun 7, 8:00 PM ET
- Accepted
- Jun 8, 9:35 PM ET
- Size
- 12.9 KB